In a milestone for American patients, AstraZeneca has announced an agreement with the U.S. government to reduce the cost of prescription medicines by up to 80%. The move is expected to make treatment for chronic conditions and cancer significantly more affordable while keeping the U.S. at the forefront of biopharmaceutical innovation. As part of the plan, AstraZeneca will offer direct-to-consumer sales through the TrumpRx.gov platform, allowing patients to purchase discounted medicines directly from the company.
The agreement also includes a $50 billion investment in U.S. manufacturing and R&D over the next five years. AstraZeneca will expand production facilities across Virginia, Texas, Maryland, and Massachusetts to ensure its medicines sold in America are made in America. CEO Pascal Soriot said the deal will help millions of Americans access life-changing therapies at lower prices while strengthening the nation’s leadership in medical innovation. The company, which employs more than 25,000 people in the U.S., created roughly $20 billion in value for the American economy in 2025.